Results for: Vivos Therapeutics

Vivos Therapeutics Inc. (VVOS) shares plunged 26.1% on Thursday after the company announced a $4.3 million registered offering of 1.36 million shares. The offering, expected to close on September 20, will generate approximately $4.3 million in gross proceeds and will be used for working capital and general corporate purposes. This news follows a recent discussion on whether VVOS is a good stock to buy, with analysts focusing on the company’s capital allocation strategy, including dividend payouts and stock buyback programs.

The stock market experienced a slight decline following the Federal Reserve’s decision to cut interest rates by 0.5%. While the Dow Jones Industrial Average, S&P 500, and Nasdaq all closed lower, several individual stocks captured attention. Nvidia saw a dip after announcing a potential acquisition, while T-Mobile’s partnership with Nvidia, Ericsson, and Nokia pushed its shares down. Vivos Therapeutics soared on FDA approval, and Tesla continued its upward trend after the rate cut.

Vivos Therapeutics, Inc. has secured FDA clearance for its flagship oral medical device, designed to treat moderate to severe obstructive sleep apnea (OSA) and snoring in children. This breakthrough paves the way for Vivos to expand its reach in the pediatric market and offer a non-invasive, effective alternative to traditional treatments.